Infect Chemother.  2019 Jun;51(2):183-187. 10.3947/ic.2019.51.2.183.

Seroprevalence of Hepatitis A Virus in Pediatric Patients with Hematologic Malignancies after Chemotherapy and Hematopoietic Cell Transplantation

• Moon JU
• Han AL
• Lee ES
• Kim SK
• Han SB
• Lee JW
• Chung NG
• Cho B
• Jeong DC
• Kang JH

• KMID: 2450875
• DOI: http://doi.org/10.3947/ic.2019.51.2.183

Abstract

This retrospective study was performed to determine the seroprevalence of hepatitis A virus (HAV) in children and adolescents with hematologic malignancies after the completion of chemotherapy and hematopoietic cell transplantation (HCT). Of 97 enrolled patients, 60 (61.9%) were seropositive for HAV. The seroprevalences in patients undergoing chemotherapy and HCT were 60.3% (41/68) and 65.5% (19/29), respectively (P = 0.628). No significant factors associated with seropositivity for HAV after chemotherapy and HCT were identified. Anti-HAV tests and HAV re-vaccinations can be considered in children and adolescents with underlying hematologic malignancies after chemotherapy and HCT based on the anti-HAV results.

Keyword

Chemotherapy; Stem cell transplantation; Hepatitis A virus; Seroprevalence; Child

MeSH Terms

Adolescent
Cell Transplantation*
Child
Drug Therapy*
Hematologic Neoplasms*
Hepatitis A Antibodies
Hepatitis A virus*
Hepatitis A*
Hepatitis*
Humans
Retrospective Studies
Seroepidemiologic Studies*
Stem Cell Transplantation
Transplants*
Hepatitis A Antibodies

Reference

1. Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015; 373:1541–1552.

2. Rubnitz JE. Current management of childhood acute myeloid leukemia. Paediatr Drugs. 2017; 19:1–10.

3. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, Kang I. Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014; 58:e44–e100.

4. Alanko S, Pelliniemi TT, Salmi TT. Recovery of blood B-lymphocytes and serum immunoglobulins after chemotherapy for childhood acute lymphoblastic leukemia. Cancer. 1992; 69:1481–1486.

5. Godoi ER, de Souza VA, Cakmak S, Machado AF, Vilas Boas LS, Machado CM. Loss of hepatitis A virus antibodies after bone marrow transplantation. Bone Marrow Transplant. 2006; 38:37–40.

6. Unal Ince E, Ertem M, Ileri T, Sayili A, Belgemen T, Uysal Z. Significant loss of hepatitis A Ab after allogeneic hematopoietic SCT in pediatric patients. Bone Marrow Transplant. 2010; 45:171–175.

7. Yalçin SS, Kondolot M, Göker H, Kuşkonmaz B, Karacan Y, Cetın M, Aksu S, Tezcan I, Uçkan D. Naturally acquired hepatitis A antibodies after haematopoetic stem cell transplantation. Epidemiol Infect. 2011; 139:683–687.

8. Köksal Y, Yalçin B, Aydin GB, Sari N, Yazici N, Varan A, Kutluk T, Akyüz C, Büyükpamukçu M. Immunogenicity of hepatitis a vaccine in children with cancer. Pediatr Hematol Oncol. 2006; 23:619–624.

9. Patel SR, Ortín M, Cohen BJ, Borrow R, Irving D, Sheldon J, Heath PT. Revaccination with measles, tetanus, poliovirus, Haemophilus influenzae type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation. Clin Infect Dis. 2007; 44:625–634.

10. Patel SR, Ortín M, Cohen BJ, Borrow R, Irving D, Sheldon J, Heath PT. Revaccination of children after completion of standard chemotherapy for acute leukemia. Clin Infect Dis. 2007; 44:635–642.

11. Korean Centers for Disease Control and Prevention (KCDC). Infectious diseases surveillance yearbook, 2017. Accessed 16 May 2019. Available at: http://www.cdc.go.kr/npt/biz/npp/portal/nppPblctDtaMain.do.

12. Yoon EL, Sinn DH, Lee HW, Kim JH. Current status and strategies for the control of viral hepatitis A in Korea. Clin Mol Hepatol. 2017; 23:196–204.

13. Carpenter PA, Englund JA. How I vaccinate blood and marrow transplant recipients. Blood. 2016; 127:2824–2832.

14. Yang HI, Park EY, Kim MY. National immunization survey in South Korea, 2013. Public Health Wkly Rep. 2014; 7:449–454.